Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial

{
  "awards": [
    {
      "id": "1",
      "items": [
        {
          "additionalClassifications": [
            {
              "description": "Pharmaceutical products",
              "id": "33600000",
              "scheme": "CPV"
            }
          ],
          "deliveryAddresses": [
            {
              "country": "GB",
              "countryName": "United Kingdom",
              "region": "UKN"
            }
          ],
          "id": "1",
          "relatedLot": "1"
        }
      ],
      "mainProcurementCategory": "goods",
      "relatedLots": [
        "1"
      ],
      "status": "active",
      "suppliers": [
        {
          "id": "GB-COH-NI041905",
          "name": "ALMAC CLINICAL SERVICES LIMITED"
        }
      ]
    }
  ],
  "buyer": {
    "id": "GB-PPON-PLQJ-5727-JCLR",
    "name": "Belfast Health \u0026 Social Care Trust"
  },
  "contracts": [
    {
      "aboveThreshold": true,
      "awardID": "1",
      "dateSigned": "2026-01-19T00:00:00Z",
      "documents": [
        {
          "datePublished": "2026-01-21T09:15:28Z",
          "description": "Contract details notice on Find a Tender",
          "documentType": "contractNotice",
          "format": "text/html",
          "id": "005092-2026",
          "noticeType": "UK7",
          "url": "https://www.find-tender.service.gov.uk/Notice/005092-2026"
        }
      ],
      "id": "1",
      "noAgreedMetricsRationale": "The Contract is below the \u00a35M threshold for KPI\u0027s",
      "period": {
        "endDate": "2030-01-05T23:59:59Z",
        "startDate": "2026-01-19T00:00:00Z"
      },
      "status": "active",
      "title": "Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial",
      "value": {
        "amount": 494447.5,
        "amountGross": 593337,
        "currency": "GBP"
      }
    }
  ],
  "date": "2026-01-21T09:15:28Z",
  "id": "005092-2026",
  "initiationType": "tender",
  "language": "en",
  "ocid": "ocds-h6vhtk-05f108",
  "parties": [
    {
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "Belfast",
        "postalCode": "BT12 6BA",
        "region": "UKN06",
        "streetAddress": "Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital"
      },
      "contactPoint": {
        "email": "FinanceProcurement@belfasttrust.hscni.net"
      },
      "details": {
        "classifications": [
          {
            "description": "Public authority - central government",
            "id": "publicAuthorityCentralGovernment",
            "scheme": "UK_CA_TYPE"
          },
          {
            "description": "Northern Irish devolved regulations apply",
            "id": "GB-NIR",
            "scheme": "UK_CA_DEVOLVED_REGULATIONS"
          }
        ]
      },
      "id": "GB-PPON-PLQJ-5727-JCLR",
      "identifier": {
        "id": "PLQJ-5727-JCLR",
        "scheme": "GB-PPON"
      },
      "name": "Belfast Health \u0026 Social Care Trust",
      "roles": [
        "buyer"
      ]
    },
    {
      "additionalIdentifiers": [
        {
          "id": "PRCD-2287-GMQG",
          "scheme": "GB-PPON"
        }
      ],
      "address": {
        "country": "GB",
        "countryName": "United Kingdom",
        "locality": "Craigavon",
        "postalCode": "BT63 5QD",
        "region": "UKN07",
        "streetAddress": "Almac House"
      },
      "contactPoint": {
        "email": "csrfinotifcations@almacgroup.com"
      },
      "details": {
        "publicServiceMissionOrganization": false,
        "scale": "large",
        "shelteredWorkshop": false,
        "url": "http://ww.almacgroup.com",
        "vcse": false
      },
      "id": "GB-COH-NI041905",
      "identifier": {
        "id": "NI041905",
        "scheme": "GB-COH"
      },
      "name": "ALMAC CLINICAL SERVICES LIMITED",
      "roles": [
        "supplier"
      ]
    }
  ],
  "tag": [
    "award",
    "contract"
  ],
  "tender": {
    "description": "This procurement is for the manufacture and testing of over encapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial",
    "documents": [
      {
        "description": "Not published",
        "documentType": "conflictOfInterest",
        "id": "conflictOfInterest"
      }
    ],
    "id": "DAC20211",
    "legalBasis": {
      "id": "2023/54",
      "scheme": "UKPGA",
      "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
    },
    "lots": [
      {
        "id": "1",
        "status": "complete"
      }
    ],
    "procurementMethod": "direct",
    "procurementMethodDetails": "Direct award",
    "procurementMethodRationale": "Schedule 5, (2) The public contract concerns the production of a prototype, or supply of other novel goods or services, for the purpose of (c) other research, experiment, study or development.\nAge-related macular degeneration (AMD) is a leading cause of visual loss. There are two main forms of AMD: dry and wet. The current wet AMD treatment is intravitreal antiVEGF injections, repeated every 4-12 weeks. Due to the cost of the medication, the route and frequency of administration, this treatment is a significant burden on the NHS budget. An additional treatment option for wet AMD is L-dopa. L-dopa is a widely available drug (used in treatment of Parkinson\u0027s), typically in the form of Carbidopa-L-Dopa. It is taken as an oral tablet and is significantly cheaper than the antiVEGF injections.\nThe study will be a placebo-controlled clinical trial. Eligible patients will be randomised to receive either 100mg L-DOPA+25mg carbidopa or placebo twice a day, for 24 months, in addition to the current standard of care to determine if this is a more cost-effective and easier-to-administer treatment regime than the current standard of care. \nTo \u0027blind\u0027 this clinical trial (to reduce bias) requires the development, manufacture and testing of over encapsulated 100mg L-DOPA+25mg carbidopa tablets and development and manufacture of matching placebo capsules. The expertise required to develop and manufacture these capsules in the quantity required for this trial requires outsourcing to a manufacturer licensed by the MHRA possessing the necessary technical expertise.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "prototypesDevelopment"
      }
    ],
    "status": "complete",
    "title": "Manufacture and testing of overencapsulated tablets and placebo capsules for research purposes - LAMDARCT clinical trial"
  }
}